Press "Enter" to skip to content

Roche’s lung cancer combo treatment wins FDA approval

Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer.

Original source:

Also Read:   Glenmark gets USFDA nod for generic version of acne treatment gel